The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer
Abstract
BACKGROUND.: The objective of this study was to evaluate the efficacy and safety of atrasentan (Xinlay), a selective endothelin‐A receptor antagonist, in patients with metastatic hormone‐refractory prostate cancer (HRPC). METHODS.: This multinational, double‐blind, placebo‐controlled trial enrolled 809 men with metastatic HRPC. Patients were randomized 1:1 to receive either atrasentan 10 mg per day or placebo. The primary endpoint was time to disease progression (TTP), which was determined according to radiographic and clinical measures. Analyses of overall survival and changes in biomarkers also were performed. RESULTS.: Atrasentan did not reduce the risk of disease progression relative to placebo (hazards ratio, 0.89; 95% confidence interval, 0.76–1.04; P = .136). Most patients progressed radiographically at the first 12‐week bone scan without concomitant clinical progression. In exploratory analyses, increases from baseline to final bone alkaline phosphatase (BAP) and prostate‐specific antigen (PSA) levels were significantly lower with atrasentan treatment (P < .05 for each). The median time to BAP progression (≥50% increase from nadir) was twice as long with atrasentan treatment (505 days vs 254 days; P < .01). The delay in time to PSA progression did not reach statistical significance. Atrasentan generally was tolerated well, and the most common adverse events associated with treatment were headache, rhinitis, and peripheral edema, reflecting the vasodilatory and fluid‐retention properties of endothelin‐A receptor antagonism. CONCLUSIONS.: Atrasentan did not delay disease progression in men with metastatic HRPC despite evidence of biologic effects on PSA and BAP as markers of disease burden. Cancer 2007. © 2007 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Petrylak, D. P., Tangen, C. M., Hussain, M. H. A., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Counting Processes and Survival Analysis.
Dabrowska, D. M., Fleming, T. R., & Harrington, D. P. (1992) · Journal of the American Statistical Association · doi:10.2307/2290673 · Cited by 2,271
Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M., Figg, W. D., Freidlin, B., Halabi, S., Hudes, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3461 · Cited by 977
Self-citationPrognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.100 · Cited by 674
Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate
Nelson, J. B., Hedican, S. P., George, D. J., Reddi, A. H., Piantadosi, S., Eisenberger, M. A., & Simons, J. W. (1995) · Nature Medicine · doi:10.1038/nm0995-944 · Cited by 622
Self-citationOsteoblasts in prostate cancer metastasis to bone
Logothetis, C. J., & Lin, S.-H. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1528 · Cited by 614
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases
Yin, J. J., Mohammad, K. S., Käkönen, S. M., Harris, S., Wu-Wong, J. R., Wessale, J. L., Padley, R. J., Garrett, I. R., Chirgwin, J. M., & Guise, T. A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1830978100 · Cited by 381
Carducci, M. A., Padley, R. J., Breul, J., Vogelzang, N. J., Zonnenberg, B. A., Daliani, D. D., Schulman, C. C., Nabulsi, A. A., Humerickhouse, R. A., Weinberg, M. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.176 · Cited by 371
Self-citationEndothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.
Nelson, J. B., Chan‐Tack, K. M., Hedican, S. P., Magnuson, S. R., Opgenorth, T. J., Bova, G. S., & Simons, J. W. (1996) · PubMed · Cited by 333
Self-citationA new parameter for measuring metastatic bone involvement by prostate cancer: the Bone Scan Index.
Imbriaco, M., Larson, S. M., YEUNG, H. W. D., Mawlawi, O. R., Erdi, Y. E., Venkatraman, E., & Scher, H. I. (1998) · PubMed · Cited by 231
Role of endothelin-1 in osteoblastic bone metastases
Guise, T. A., Yin, J. J., & Mohammad, K. S. (2003) · Cancer · doi:10.1002/cncr.11129 · Cited by 228
Opgenorth, T. J., Adler, A. L., Calzadilla, S. V., Chiou, W. J., Dayton, B. D., Dixon, D. B., Gehrke, L. J., Hernandez, L., Magnuson, S. R., Marsh, K. C., et al. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12297-0 · Cited by 211
Endothelin-1: a multifunctional molecule in cancer
Grant, K., Loizidou, M., & Taylor, I. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6700750 · Cited by 184
Carducci, M. A., Nelson, J. B., Kathy Bowling, M., Rogers, T., Eisenberger, M. A., Sinibaldi, V., Donehower, R., Leahy, T. L., Carr, R. A., Isaacson, J. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.028 · Cited by 159
Self-citationFizazi, K. S., Yang, J., Peleg, S., Sikes, C. R., Kreimann, E. L., Daliani, D., Olivé, M., Raymond, K. A., Janus, T. J., Logothetis, C. J., et al. (2003) · PubMed · Cited by 147
Bufalo, D. D., Castro, V. D., Biroccio, A., Varmi, M., Salani, D., Rosanò, L., Trisciuoglio, D., Spinella, F., & Bagnato, A. (2002) · Molecular Pharmacology · doi:10.1124/mol.61.3.524 · Cited by 142
The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae
Takuwa, Y., Masaki, Τ., & Yamashita, K. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)90491-5 · Cited by 129
Vacca, F., Bagnato, A., Catt, K. J., et al. (2000) · PubMed · Cited by 127
Update of REACH-1 and MERIT-HF Clinical Trials in Heart Failure
Mylona, P., Cleland, J. G. F., & The Cardio.net Editorial Team (1999) · European Journal of Heart Failure · doi:10.1016/s1388-9842(99)00022-7 · Cited by 118
Eiberg, H. (1998) · European Urology · doi:10.1159/000052240 · Cited by 77
Endothelin Inhibition: Novel Therapy for Prostate Cancer
Nelson, J. B. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000096372.07687.86 · Cited by 62
Self-citationSylvester, R. J., Denis, L., & de Voogt, H. J. (1998) · European Urology · doi:10.1159/000019545 · Cited by 44
Jørgensen, T. L., Kanagasingam, Y., Kaalhus, O., Tveter, K. J., Bryne, M., Skjørten, F., Berner, A., & Danielsen, H. E. (1997) · The Journal of Urology · doi:10.1097/00005392-199707000-00052 · Cited by 42
Endothelin-1 and osteoblastic metastasis
Mundy, G. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2035063100 · Cited by 25
Canine prostate stimulates osteoblast function using the endothelin receptors
LeRoy, B. E., Sellers, R. S., & Rosol, T. J. (2003) · The Prostate · doi:10.1002/pros.10370 · Cited by 16
Endothelin Expression and the Progression of Heart Failure
Konstam, M. A., & DeNofrio, D. (2004) · Circulation · doi:10.1161/01.cir.0000110644.92116.91 · Cited by 16
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Geiger, T. R., & Peeper, D. S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.006 · Cited by 431
Bone metastasis: mechanisms, therapies, and biomarkers
Clézardin, P., Coleman, R., Puppo, M., Ottewell, P., Bonnelye, E., Paycha, F., Confavreux, C. B., & Holen, I. (2021) · Physiological Reviews · doi:10.1152/physrev.00012.2019 · Cited by 416
Endothelin 1 in cancer: biological implications and therapeutic opportunities
Rosanò, L., Spinella, F., & Bagnato, A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3546 · Cited by 348
Metadata
- Authors
- Carducci, M. A., Saad, F., Abrahamsson, P., Dearnaley, D. P., Schulman, C. C., North, S. A., Sleep, D. J., Isaacson, J. D., Nelson, J. B., & for the Atrasentan Phase III Study Group Institutions.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-10-18
- Volume
- 110
- Issue
- 9
- Pages
- 1959-1966
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2042692879
- Cited by
- 294
- References
- 27
- FWCI
- 27.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.